


Stabilis



Lorazepam



Товарное название

Ativan	Великобритания, Ирландия, новая Зеландия, Соединённые Штаты Америки
Tavor	Греция, Италия, Словения, Эквадор
Temesta	Австрия, Голландия, Люксембург, Словения, Швейцария



Стабильность растворов

		0,038 mg/ml	21°C		24			350
		0,167 mg/ml	2-8°C		1			4248
		0,167 mg/ml	20-25°C		1			4248
		1 & 2 mg/ml	22°C		28			765
		2 mg/ml	4°C-10°C		210			1424
		0,038 mg/ml	21°C		24			350
		1 mg/ml	25°C		24			935
		0,038 mg/ml	21°C		24			350
		0,1 mg/ml	-20°C		7			175
		0,1 mg/ml	24°C		7			175
		0,1 mg/ml	37°C		3			175
		0,1 mg/ml	4°C		7			175
		0,91 mg/ml	-20°C		35			1935

POF	▲	0,91 mg/ml	24°C	?	35	☾		1935
POF	▲	0,91 mg/ml	37°C	?	5	☾		1935
POF	▲	0,91 mg/ml	4°C	?	35	☾		1935
POF	◆	0,1 mg/ml	-20°C	☀	7	☾		175
POF	◆	0,1 mg/ml	24°C	☀	7	☾		175
POF	◆	0,1 mg/ml	37°C	☀	3	☾		175
POF	◆	0,1 mg/ml	4°C	☀	7	☾		175
POF	◆	0,2 mg/ml	25°C	☀	24	☑		2146
POF	RL	0,1 mg/ml	-20°C	☀	7	☾		175
POF	RL	0,1 mg/ml	24°C	☀	7	☾		175
POF	RL	0,1 mg/ml	37°C	☀	3	☾		175
POF	RL	0,1 mg/ml	4°C	☀	7	☾		175
PP	▲	0,167 mg/ml	2-8°C	?	2	☾		4248
PP	▲	0,167 mg/ml	20-25°C	?	4	☾		4248
PP	▲	1 mg/ml	22°C	☀	28	☑		765
PP	◆	1 mg/ml	22°C	☀	28	☑		765



Стабильность смесей

	▲	0,05 mg/ml	20°C-23°C	☀	Granisetron hydrochloride : 0,5 mg/ml	4	☑ 57
	▲	1 mg/ml	25°C	?	Fosphenytoin sodium : 5 mg/ml	8	☑ 1419
	◆	0,25 mg/ml	20°C-25°C	?	Palonosetron hydrochloride : 25 µg/ml	4	☑ 1975
	◆	0,1 mg/ml	22°C-23°C	☀	Milrinone lactate : 0,2 mg/ml	4	☑ 813
	◆	0,028 mg/ml	25°C	☀	Ondansetron hydrochloride : 0,44 mg/ml Dexamethasone sodium phosphate : 0,28 mg/ml	24	☑ 25
PP	▲	0.16 mg/ml	25°C	☀	Dexamethasone sodium phosphate : 0.27 mg/ml Diphenhydramine hydrochloride : 4 mg/ml	48	☑ 2132



Факторы, которые влияют на стабильность

		→		1415
		→		24
				25
				175

				177
				532
				233
	[0,5 mg / ml]			780



Совместимость

	Lorazepam : 0.04 mg/ml Aciclovir sodium : 5 mg/ml		336
		Lorazepam : 2 mg/ml Aldesleukin : 0.0338 MUI/ml	36
	Lorazepam : 0.1 mg/ml Allopurinol sodium : 3 mg/ml		307
	Lorazepam : 0.1 mg/ml Amifostine : 10 mg/ml		3
	Lorazepam : 0.33 mg/ml Amikacin sulfate : 5 mg/ml		186
	Lorazepam : 1 mg/ml Amiodarone hydrochloride : 6 mg/ml		1611
	Lorazepam : 0.33 mg/ml Amoxicillin sodium : 50 mg/ml		186
	Lorazepam : 4 mg/ml Amoxicillin sodium / clavulanic acid : 100/10 mg/ml		3824
	Lorazepam : 0.33 mg/ml Amoxicillin sodium / clavulanic acid : 20/2 mg/ml		186
	Lorazepam : 0.1 mg/ml Amphotericin B cholesteryl sulfate complex : 0.83 mg/ml		921
	Lorazepam : 0.1 mg/ml Amsacrine : 1 mg/ml		253
	Lorazepam : 0.5 mg/ml Atracurium besylate : 0.5 mg/ml		402
		Lorazepam : 0.1 mg/ml Aztreonam : 40 mg/ml	99
		Lorazepam : 0.8 & 1.33 mg/ml Benztropine mesylate : 0.67 & 0.8 mg/ml	1724
	Lorazepam : 0.5 mg/ml Bivalirudin		3539
		Lorazepam : 2 mg/ml Bivalirudin	3539
	Lorazepam : 0.5 mg/ml Bivalirudin : 5 mg/ml		1713
	Lorazepam : 0.33 mg/ml Bumetanide : 0.5 mg/ml		186
		Lorazepam : 4 mg/ml Caffeine : 10 mg/ml	3964
	Lorazepam : 0,5 mg/ml Caspofungin acetate : 0,7 mg/ml		2247

		Lorazepam : 1 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL		4528
		Lorazepam : 1 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL		4528
		Lorazepam : 4 mg/ml Cefmetazole sodium : 100 mg/ml		93
		Lorazepam : 0.33 mg/ml Cefotaxime sodium : 10 mg/ml		186
		Lorazepam : 0,5 mg/ml Ceftaroline fosamil : 2,22 mg/ml	RL	3249
		Lorazepam : 0,5 mg/ml Ceftaroline fosamil : 2,22 mg/ml		3249
		Lorazepam : 0,5 mg/ml Ceftaroline fosamil : 2,22 mg/ml		3249
		Lorazepam : 0.5 mg/ml Ceftobiprole medocartil sodium : 2 mg/ml	RL	2269
		Lorazepam : 0.5 mg/ml Ceftobiprole medocartil sodium : 2 mg/ml		2269
		Lorazepam : 0.5 mg/ml Ceftobiprole medocartil sodium : 2 mg/ml		2269
		Lorazepam : 1 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828
		Lorazepam : 1 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828
		Lorazepam : 0.44 & 0.8 mg/ml Chlorpromazine hydrochloride : 20 & 22.22 mg/ml		1724
		Lorazepam : 2 mg/ml Cimetidine hydrochloride : 150 mg/ml		1438
		Lorazepam : 0.33 mg/ml Ciprofloxacin lactate : 2 mg/ml		186
		Lorazepam : 0.5 mg/ml Cisatracurium besylate : 0.1 >> 5 mg/ml		299
		Lorazepam : 0.1 mg/ml Cladribine : 0.015 mg/ml		1496
		Lorazepam : 0.1 mg/ml Cladribine : 0.5 mg/ml		1496
		Lorazepam : 0.33 mg/ml Clonidine hydrochloride : 0.015 mg/ml		186
		Lorazepam : 4 mg/ml Cloxacillin sodium : 100 mg/ml		3012
		Lorazepam : 0.33 mg/ml Co-trimoxazole : 0.8/4 mg/ml		186
		Lorazepam : 0.33 mg/ml Dexamethasone sodium phosphate : 4 mg/ml		186
		Lorazepam : 0.5 mg/ml Dexmedetomidine : 4 µg/ml		1712
		Lorazepam : 4 mg/ml Diltiazem hydrochloride : 5 mg/ml		198
		Lorazepam : 2 mg/ml Diltiazem hydrochloride : 1 mg/ml		198
		Lorazepam : 0.5 mg/ml Diltiazem hydrochloride : 1 mg/ml		314

	Lorazepam Dimenhidrate		2087
	Lorazepam : 0.5 mg/ml Dobutamine hydrochloride : 4 mg/ml		314
	Lorazepam : 0.5 mg/ml Docetaxel : 0.9 mg/ml		1754
	Lorazepam : 0.5 mg/ml Dopamine hydrochloride : 3.2 mg/ml		314
	Lorazepam : 0,5 mg/ml Doripenem : 5 mg/ml		2262
	Lorazepam : 0,5 mg/ml Doripenem : 5 mg/ml		2262
	Lorazepam : 0.1 mg/ml Doxorubicin hydrochloride liposome peg : 0.4 mg/ml		251
	Lorazepam : 0.1 mg/ml Famotidine : 2 mg/ml		215
	Lorazepam : 4 mg/ml	RL	4603
	Lorazepam : 0.5 mg/ml Epinephrine hydrochloride : 20 µg/ml		314
	Lorazepam : 0.5 mg/ml Etoposide phosphate : 5 mg/ml		1410
	Lorazepam : 0.5 mg/ml Fentanyl citrate : 50 µg/ml		314
	Lorazepam : 0.1 mg/ml		301
	Lorazepam : 2 mg/ml Etomidate : 2 mg/ml		319
	Lorazepam : 0.1 mg/ml		1415
	Lorazepam : 0.33 mg/ml Erythromycin lactobionate : 5 mg/ml		186
	Lorazepam : 0.5 mg/ml Fenoldopam mesylate : 80 µg/ml		1803
	Lorazepam : 0.33 mg/ml Fentanyl citrate : 50 µg/ml		186
	Lorazepam : 0.1 mg/ml Fentanyl citrate : 25 µg/ml		1974
	Lorazepam : 0.1 mg/ml Filgrastim : 30 µg/ml		244
	Lorazepam : 0.33 mg/ml Flucloxacillin sodium : 50 mg/ml		186
	Lorazepam : 0.33 mg/ml Fluconazole : 2 mg/ml		186
	Lorazepam : 0.1 mg/ml Fludarabine phosphate : 1 mg/ml		492
	Lorazepam : 4 mg/ml Foscarnet sodium : 24 mg/ml		73
	Lorazepam : 0,08 mg/ml Foscarnet sodium : 24 mg/ml		1135
	Lorazepam : 0,08 mg/ml Foscarnet sodium : 24 mg/ml		1135
	Lorazepam : 1 mg/ml Fosfomycin : 30 mg/ml		4055

		Lorazepam : 1 mg/ml Fosfomycin : 30 mg/ml		4055
		Lorazepam		4992
		Lorazepam : 1 mg/ml Fosphenytoin sodium : 5 mg/ml		1419
		Lorazepam : 0.5 mg/ml Furosemide : 10 mg/ml		314
		Lorazepam : 0.33 mg/ml Furosemide : 10 mg/ml		186
		Lorazepam : 1 mg/ml Gallium nitrate : 1 mg/ml		91
		Lorazepam : 0.5 mg/ml Gemcitabine hydrochloride : 10 mg/ml		1423
		Lorazepam : 0.33 mg/ml Gentamicin sulfate : 3 mg/ml		186
		Lorazepam Glycopyrronium bromide		3599
		Lorazepam : 0.1 mg/ml Granisetron hydrochloride : 0.05 mg/ml		182
		Lorazepam : 0.1 mg/ml Granisetron hydrochloride : 1 mg/ml		57
		Lorazepam : 0.33 mg/ml Haloperidol lactate : 0.5 & 5 mg/ml		186
		Lorazepam : 0.33 mg/ml Heparin sodium : 417 UI/ml		186
		Lorazepam : 0.5 mg/ml Heparin sodium : 100 UI/ml		314
		Lorazepam : 0.5 mg/ml Hetastarch : 60 mg/ml		1721
		Lorazepam		4992
		Lorazepam : 0.33 mg/ml Human albumin : 200 mg/ml		186
		Lorazepam Hyaluronidase		3617
		Lorazepam : 0.33 mg/ml Hydrocortisone sodium succinate : 50 mg/ml		186
		Lorazepam : 0.1 mg/ml Hydromorphone hydrochloride : 0.5 mg/ml		1974
		Lorazepam : 0.5 mg/ml Hydromorphone hydrochloride : 1 mg/ml		314
		Lorazepam : 4 mg/ml Hydromorphone hydrochloride : 2 >> 40 mg/ml		1497
		Lorazepam : 2 mg/ml Idarubicin hydrochloride : 1 mg/ml		491
		Lorazepam : 0.33 mg/ml Imipenem - cilastatin sodium : 5 mg/ml		186
		Lorazepam : 1 mg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
		Lorazepam : 1 mg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
		Lorazepam : 4 mg/ml Ketamine hydrochloride : 50 mg/ml		2109

		Lorazepam : 4 mg/ml Ketamine hydrochloride : 50 mg/ml		4389
		Lorazepam : 0.5 mg/ml Labetalol hydrochloride : 2 mg/ml		314
		Lorazepam : 0.5 mg/ml Lansoprazole : 0.55 mg/ml		1625
		Lorazepam : 2 mg/ml Levofloxacin : 5 mg/ml		1072
		Lorazepam : 0.1 mg/ml Linezolid : 2 mg/ml		1925
		Lorazepam : 1.33 >> 2.67 mg/ml Loxapine : 16.67 >> 33.3 mg/ml		1724
		Lorazepam : 0.1 mg/ml Melfalan : 0.1 mg/ml		169
		Lorazepam : 0.1 mg/ml Methadone hydrochloride : 1 mg/ml		1974
		Lorazepam : 0.33 mg/ml Metronidazole : 5 mg/ml		186
		Lorazepam : 0.5 mg/ml Miconazole : 1.5 mg/ml		2108
		Lorazepam : 0.5 mg/ml Midazolam hydrochloride : 2 mg/ml		314
		Lorazepam : 0.5 mg/ml Milrinone lactate : 0.2 mg/ml		314
		Lorazepam : 0.4 mg/ml Milrinone lactate : 0.8 mg/ml		813
		Lorazepam : 0.33 mg/ml Morphine hydrochloride : 1 mg/ml		186
		Lorazepam : 0.5 mg/ml Morphine sulfate : 2 mg/ml		314
		Lorazepam : 0.1 mg/ml Morphine sulfate : 1 mg/ml		1974
		Lorazepam : 4 mg/ml Naloxone hydrochloride : 0.4 mg/ml		3408
		Lorazepam : 0.5 mg/ml Nicardipine hydrochloride : 1 mg/ml		314
		Lorazepam : 0.5 mg/ml Nitroglycerin : 0.4 mg/ml		314
		Lorazepam : 0.5 mg/ml Norepinephrine bitartrate : 0.128 mg/ml		314
		Lorazepam : 0.33 mg/ml Omeprazole sodium : 4 mg/ml		186
		Lorazepam : 0.1 mg/ml Ondansetron hydrochloride : 1 mg/ml		334
		Lorazepam : 1 mg/ml Oritavancin : 0.8 >> 2 mg/ml		3152
		Lorazepam : 0.5 mg/ml Oxaliplatin : 0.5 mg/ml		1662
		Lorazepam : 0.1 mg/ml Paclitaxel : 1.2 mg/ml		85
		Lorazepam : 0.5 mg/ml Palonosetron hydrochloride : 50 µg/ml		1975

		Lorazepam : 0.5 mg/ml Pancuronium bromide : 0.05 mg/ml		402
		Lorazepam Pantoprazole sodium		2090
		Lorazepam : 4 mg/ml Paracetamol : 10 mg/ml		4742
		Lorazepam : 0.5 mg/ml Pemetrexed disodium : 20 mg/ml		1953
		Lorazepam : 0.33 mg/ml Piperacillin sodium : 150 mg/ml		186
		Lorazepam : 0.1 mg/ml Piperacillin sodium / tazobactam : 40/5 mg/ml		81
		Lorazepam : 1 mg/ml Plazomicin sulfate : 24 mg/ml		4145
		Lorazepam Posaconazole		4380
		Lorazepam : 0.33 mg/ml Potassium chloride : 1000 mEq/l		186
		Lorazepam : 2 mg/ml Propofol : 2 mg/ml		319
		Lorazepam : 0.1 mg/ml Propofol : 10 mg/ml		300
		Lorazepam : 4 mg/ml Ranitidine hydrochloride : 25 mg/ml		58
		Lorazepam : 0.33 mg/ml Ranitidine hydrochloride : 0.5 mg/ml		186
		Lorazepam : 0.5 mg/ml Ranitidine hydrochloride : 1 mg/ml		314
		Lorazepam : 0.5 mg/ml Remifentanyl hydrochloride : 25 & 250 µg/ml		59
		Lorazepam : 4 mg/ml Salbutamol sulfate : 1 mg/ml		3216
		Lorazepam : 0.1 mg/ml Sargramostim : 10 µg/ml		335
		Lorazepam : 0.1 mg/ml Sargramostim : 10 µg/ml		335
		Lorazepam : 1 mg/ml Sulbactam/durlobactam : 15/15 mg/ml		4801
		Lorazepam : 1 mg/ml Tacrolimus : 1000 µg/ml		479
		Lorazepam : 1 mg/ml Tedizolid phosphate : 0.8 mg/ml		3827
		Lorazepam : 0.1 mg/ml Teniposide : 0.1 mg/ml		905
		Lorazepam : 0.5 mg/ml Thiopental sodium : 25 mg/ml		314
		Lorazepam : 2 mg/ml Thiopental sodium : 25 mg/ml		319
		Lorazepam : 4 mg/ml Thiopental sodium : 25 mg/ml		3767
		Lorazepam : 0.1 mg/ml Thiotepa : 1 mg/ml		249

	Lorazepam : 1 mg/ml Valproic acid : 2 & 20 mg/ml		4428
	Lorazepam : 1 mg/ml Valproic acid : 2 & 20 mg/ml		4428
	Lorazepam : 0.33 mg/ml Vancomycin hydrochloride : 5 mg/ml		186
	Lorazepam : 0.5 mg/ml Vecuronium bromide : 1 mg/ml		314
	Lorazepam : 0.33 mg/ml Vecuronium bromide : 4 mg/ml		186
	Lorazepam : 0.5 mg/ml Vecuronium bromide : 0.1 mg/ml		402
	Lorazepam : 0.1 mg/ml Vinorelbine tartrate : 1 mg/ml		84
	Lorazepam : 0.08 mg/ml Zidovudine : 4 mg/ml		337



Способы введения



Библиография

	ТИП	публикация
3	Журнал	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
24	Журнал	Stiles ML, Allen LV Jr, Prince SJ, Holland JS. Stability of dexamethasone sodium phosphate, diphenhydramine hydrochloride, lorazepam, and metoclopramide hydrochloride in portable infusion-pump reservoirs. Am J Hosp Pharm 1994 ; 51: 514-517.
25	Журнал	McGuire TR, Narducci WA, Fox JL. Compatibility and stability of ondansetron hydrochloride, dexamethasone, and lorazepam in injectable solutions. Am J Hosp Pharm 1993 ; 50: 1410-1414.
36	Журнал	Alex S, Gupta SL, Minor JR, Turcovski-Corrales S, Gallelli JF, Taub D, Piscitelli SC. Compatibility and activity of aldesleukin (recombinant interleukin-2) in presence of selected drugs during simulated Y-site administration: Evaluation of three methods. Am J Health-Syst Pharm 1995 ; 52: 2423-2426.
57	Журнал	Mayron D, Gennaro AR. Stability and compatibility of granisetron hydrochloride in IV solutions and oral liquids and during simulated Y-site injection with selected drugs. Am J Health-Syst Pharm 1996 ; 53: 294-304.
58	Журнал	Parker WA. Physical compatibility of ranitidine HCl with preoperative injectable medications. Can J Hosp Pharm 1985 ; 38: 160-161.
59	Журнал	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanyl hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.

73	Журнал	Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159.
81	Журнал	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	Журнал	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
85	Журнал	Trissel LA, Bready BB. Turbidimetric assessment of the compatibility of taxol with selected other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 1716-1719.
91	Журнал	Lober CA, Dollard PA. Visual compatibility of gallium nitrate with selected drugs during Y-site injection. Am J Hosp Pharm 1993 ; 50: 1208-1210.
93	Журнал	Hutchings SR, Rusho WJ, Tyler LS. Compatibility of cefmetazole sodium with commonly used drugs during Y-site delivery. Am J Health-Syst Pharm 1996 ; 53: 2185-2188.
99	Журнал	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
169	Журнал	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
175	Журнал	Trissel LA, Pearson SD. Storage of lorazepam in three injectable solutions in polyvinyl chloride and polyolefin bags. Am J Hosp Pharm 1994 ; 51: 368-372.
177	Журнал	Mancano MA, Boullata JJ, Gelone SP, Zitterman RE, Borenstein MR. Availability of lorazepam after simulated administration from glass and polyvinyl chloride containers. Am J Health-Syst Pharm 1995 ; 52: 2213-2216.
182	Журнал	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
186	Журнал	Swart EL, Mooren RAG, Van Loenen AC. Compatibility of midazolam hydrochloride and lorazepam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2020-2022.
198	Журнал	Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520.
215	Журнал	Keyi X, Gagnon N, Bisson C, Desmarais M, LeBel M. Stability of famotidine in polyvinyl chloride minibags and polypropylene syringes and compatibility of famotidine with selected drugs. Ann Pharmacotherapy 1993 ; 27: 422-426.
233	Журнал	Grillo JA, Barie PS. Precipitation of lorazepam during infusion by volumetric pump. Am J Health-Syst Pharm 1996 ; 53: 1850.
244	Журнал	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.

249	Журнал	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Журнал	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
253	Журнал	Trissel LA, Chandler SW, Folstad JT. Visual compatibility of amsacrine with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 2525-2528.
299	Журнал	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300	Журнал	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Журнал	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	Журнал	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
314	Журнал	Chiu MF, Schwartz ML. Visual compatibility of injectable drugs used in the intensive care unit. Am J Health-Syst Pharm 1997 ; 54: 64-65.
319	Журнал	Hadzija BW, Lubarsky DA. Compatibility of etomidate, thiopental sodium, and propofol injections with drugs commonly administered during induction of anesthesia. Am J Health-Syst Pharm 1995 ; 52: 997-999.
334	Журнал	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	Журнал	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplastic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
336	Журнал	Forman JK, Lachs JR, Souney PF. Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection. Am J Hosp Pharm 1987 ; 44: 1408-1409.
337	Журнал	Bashaw ED, Amantea MA, Minor JR, Galleli JF. Visual compatibility of zidovudine with other drugs during simulated Y-site administration. Am J Hosp Pharm 1988 ; 45: 2532-2533.
350	Журнал	Martens HJ, De Goede PN, Van Loenen AC. Sorption of various drugs in polyvinyl chloride, glass, and polyethylene-lined infusion containers. Am J Hosp Pharm 1990 ; 47: 369-373.
402	Журнал	Savitsky ME. Visual compatibility of neuromuscular blocking agents with various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 820-821.
479	Журнал	Min DI, Brown T, HWang GC. Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 2964-2966.

491	Журнал	Turowski RC, Durthaler JM. Visual compatibility of idarubicin hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2181-2184.
492	Журнал	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
532	Журнал	Hoey LL, Vance-Bryan K, Clarens DM, Wright DH, Konstantinides FN, Guay DRP. Lorazepam stability in parenteral solutions for continuous intravenous administration. Ann Pharmacotherapy 1996 ; 30: 343-346.
765	Журнал	Share MJ, Harrison RD, Folstad J, Fleming RA. Stability of lorazepam 1 and 2 mg/ml in glass bottles and polypropylene syringes. Am J Health-Syst Pharm 1998 ; 55: 2013-2015.
780	Журнал	Boullata J, Gelone SP, Mancano MA, Borenstein MR, Zitterman R. Precipitation of lorazepam infusion. Ann Pharmacotherapy 1996 ; 30: 1037-1038.
813	Журнал	Akkermann SR, Zhang H, Mullins RE, Yaughn K. Stability of milrinone lactate in the presence of 29 critical care drugs and 4 IV solutions. Am J Health-Syst Pharm 1999 ; 56: 63-68.
905	Журнал	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	Журнал	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
935	Журнал	Das Gupta V, Pramur Y. Stability of lorazepam in 5% dextrose injection. Int J Pharm Compound 1998 ; 2: 322-324.
1072	Журнал	Saltsmann CL, Tom CM, Mitchell A, Fan JH, Gailey RA. Compatibility of levofloxacin with 34 medications during simulated Y-site administration. Am J Health-Syst Pharm 1999 ; 56: 1458-1459.
1135	Журнал	Baltz JK, Kennedy P, Minor JR, Gallelli J. Visual compatibility of foscarnet with other injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1990 ; 47: 2075-2077.
1410	Журнал	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Журнал	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1419	Журнал	Riggs RM, English BA, Webster AA, McGuire JM, Riordan JM. Fosphenytoin Y-site stability studies with lorazepam and midazolam hydrochloride. Int J Pharm Compound 1999 ; 3: 235-238.
1423	Журнал	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1424	Журнал	Gottwald MD, Akerd LC, Liu PK, Orsulak PJ, Corry M, Bacchetti P, Fields SM, Loxenstein DH, Alldredge BK. Prehospital stability of diazepam and lorazepam. Am J Emerg Med 1999 ; 17: 333-337.
1438	Журнал	Souney PF, Solomon MA, Stancher D. Visual compatibility of cimetidine hydrochloride with common preoperative injectable medications. Am J Hosp Pharm 1984 ; 41: 1840-1841.

1496	Журнал	Trissel LA, Martinez JF, Gilbert DL. Screening cladribine for Y-site physical compatibility with selected drugs. Hosp Pharm 1996 ; 31: 1425-1428.
1497	Журнал	Walker SE, Iazetta J, DeAngelis C, Lau DWC. Stability and compatibility of combinations of hydromorphone and dimenhydrinate lorazepam or prochlorperazine. Can J Hosp Pharm 1993 ; 46: 61-65.
1611	Журнал	Chalmers JR, Bobek MB, Militello MA. Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs. Am J Health-Syst Pharm 2001 ; 58: 504-506.
1625	Журнал	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1662	Журнал	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1712	Журнал	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	Журнал	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	Журнал	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1724	Журнал	Elbe D, Condé C. Visual compatibility of various injectable neuroleptic agents with benztropine and lorazepam in polypropylene syringes. Can J Hosp Pharm 2001 ; 54: 102-105.
1754	Журнал	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1803	Журнал	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1925	Журнал	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1935	Журнал	Norenberg JP, Achusim LE, Steel TH, Anderson TL. Stability of lorazepam in 0.9% sodium chloride stored in polyolefin bags. Am J Health-Syst Pharm 2004 ; 61: 1039-1041.
1953	Журнал	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1974	Журнал	Chandler SW, Trissel LA, Weinstein SM Combined administration of opioids with selected drugs to manage pain and other cancer symptoms initial safety screening for compatibility. J Pain Symptom Manage 1996 ; 12, 3: 168-171.
1975	Журнал	Trissel LA, Xu QA. Physical and chemical stability of palonosetron hydrochloride with lorazepam and midazolam hydrochloride during simulated Y-site administration. Int J Pharm Compound 2005 ; 9, 3: 235-237.

2087	Журнал	Ferreira E, Forest JM, Hildgen P. Compatibility of dimenhydrinate injectable by Y administration. Pharmactuel 2004 ; 37: 17-20.
2090	Журнал	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2108	Журнал	Trusley C, Kupiec TC, Trissel LA. Compatibility of micafungin injection with other drugs during simulated Y-site co-administration. Int J Pharm Compound 2006 ; 10: 230-232.
2109	Журнал	Pelletier E, Forest JM, Hildgen P. Compatibilité de la kétamine injectable lors de l'administration en dérivé avec d'autres médicaments usuels. Pharmactuel 2006 ; 39: 71-75.
2132	Журнал	Anderson Collin R, Halford Zachery, MacKay Mark. Stability of Diphenhydramine Hydrochloride, Lorazepam, and Dexamethasone Sodium Phosphate in 0.9% Sodium Chloride Stored in Polypropylene Syringes. Int J Pharm Compound 2015 ; 19, 4 : 344-347.
2146	Журнал	Trissel LA, Xu QA, Baker M. Drug compatibility with new polyolefin infusion solution containers. Am J Health-Syst Pharm 2006 ; 63: 2379-2382.
2247	Журнал	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
2262	Журнал	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmore T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administration Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269	Журнал	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaryl with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
3012	Журнал	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3152	Журнал	Kumar A, Mann HJ. Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration. Am J Health-Syst Pharm 2010 ; 67: 1640-1644.
3216	Журнал	Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G. Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y. Pharmactuel 2011 ; 44, 1 : 14-18
3249	Журнал	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3408	Журнал	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d'autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3539	Лаборатория	Bivalirudin (Angiox®) - Summary of Product Characteristics. The Medecines Company 2013
3599	Лаборатория	Glycopyrrolate Injection U.S.P. - Summary of Product Characteristics Amco Amdipharm Mercry 2013
3617	Лаборатория	Hyaluronidase (Hyalase®) - Summary of Product Characteristics Wockhardt 2011


3767	Журнал	Legrís M.E, Lavoie A, Forrest J.M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172.
3824	Журнал	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3827	плакат	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	плакат	Thabit A.K, Hamada Y, Nicolau D.P. Ceftazolidime/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	плакат	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavanazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3964	Журнал	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
4055	Журнал	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	Журнал	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4248	Журнал	Colsol M.L, Breuer A, Goderniaux N, Hecq J.D, Soumoy L, Bihin B, Jamart J, Galanti L. Long-Term Stability of Lorazepam in Sodium Chloride 0.9% Stored at Different Temperatures in Different Containers. Hosp Pharm 2019 ; 55, 3: 199-193.
4380	Лаборатория	Posaconazole (Noxafil®) - Summary of Product Characteristics Merck Sharp & Dohme Limited 2019
4389	Журнал	Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G. Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévamisole et la kétamine. Pharmactuel 2019 ;52,4:206-213
4428	Журнал	Rashed S.M, Sweatman T.W, Thoma L, Hovinga C.A, Phelps S.J. Chemical Compatibility of Depacon® with Medications Frequently Administered by Intravenous Y-Site Delivery in Patients with Epilepsy or Head Trauma. J Pediatr Pharmacol Ther 2004 ; 9, 2: 126-132.
4528	Журнал	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4603	Журнал	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer's Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4742	Журнал	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l'acétaminophène injectable avec 102 autres médicaments lors d'une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.

4801	Журнал	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:
4992	Лаборатория	LORAZEPAM XILMAC 4 mg/mL, solution injectable - Résumé des caractéristiques du produit. MACURE HEALTHCARE LTD. 2024

Stabilis



Lorazepam



Стабильность фармацевтических препаратов

		30 mg ® = Mylan	Вода для инъекций 13 mL OraPlus® 7,5 mL Orasweet® 9,5 mL	21,5-22,5°C	91			4418
		30 mg ® = Watson laboratories	Orasweet® 13,5 mL OraPlus® 12,5 mL Вода для инъекций 4 mL	21,5-22,5°C	42			4418
		30 mg ® = Mylan	Вода для инъекций 13 mL OraPlus® 7,5 mL Orasweet® 9,5 mL	3-5°C	91			4418
		30 mg ® = Watson laboratories	Orasweet® 13,5 mL OraPlus® 12,5 mL Вода для инъекций 4 mL	3-5°C	91			4418
		mg/ml ® = Lorazepam Intensol		25°C	180			5110
		150 mg ® = ? (Fagron)	SyrSpend SF PH4® >>150 ml	2-8°C	90			3846
		150 mg ® = ? (Fagron)	SyrSpend SF PH4® >>150 ml	20-25°C	60			3846
		2 mg ® = West Ward Pharmaceuticals	>> 1 mL	2-8°C	60			4846
		2 mg ® = West Ward Pharmaceuticals	>> 1 mL	20-25°C	60			4846



Библиография

	ТИП	публикация
3846	Журнал	Polonini HC, Silva SL, Cunha CN, Brand?o MAF, Ferreira AO. Compatibility of cholecalciferol, haloperidol, imipramine hydrochloride, levodopa/carbidopa, lorazepam, minocycline hydrochloride, tacrolimus monohydrate, terbinafine, tramadol hydrochloride and valsartan in SyrSpend® SF PH4 oral suspensions. Pharmazie 2016 71: 185?191.
4418	Журнал	Ellaria Lee W-M, Lugo R.A, Rusho W.J, MacKay M, Sweeley J. Chemical Stability of Extemporaneously Prepared Lorazepam Suspension at Two Temperatures. J Pediatr Pharmacol Ther 2004 ; 9, 4: 254-258.
4846	Журнал	Brown S.D, Sergeant S, Morris S, Tubolino M, Coffey T. Chemical Stability of Lorazepam Oral Solution Repackaged in Plastic Oral Syringes at Room and Refrigerated Temperature. Hosp Pharm 2024 ; 59, 4
5110	Журнал	Owczarzak C, Woytowicz S, Zhao F, Rochani A. Stability Study of Lorazepam Oral Solution Repackaged in Amber Colored ENFit Oral Syringes. J Pediatr Pharmacol Ther 2025 ;30(5):630–637.



Словарь

	Анксиолитик		Инъекция
	Товарное название		Стабильность растворов
	Упаковка		Молекула Molekula
	Концентрация		Температура
	Хранение		Продолжительность стабильности
	биоподобие		противоречивые данные
	Ссылки		Стекло
	Натрия хлорид 0,9%		Защищён от света
	Час		Не указано
	День		Глюкоза 5%
	Свет		Нет
	Поливинилхлорид		Полиэтилен
	Полиолефин		Раствор Рингера лактата
	Шприц полипропилен		Стабильность смесей
	Растворитель		Молекула
	Полипропилен		Факторы, которые влияют на стабильность
	Парентеральное питание (с липидами)		Стимулирует
	Деградация		Адсорбция
	Абсорбция		Перистальтический насос
	Осадок		Совместимость
	совместимый		Немедленные осадки
	несовместимый		Мутность за один час
	Неопределенная несовместимость		Вода для инъекций
	NaCl 0,9% + антибактериальный		Мутность за 4 часа
	Парентеральное питание (бинарная смесь)		Нестабильность эмульсии через 1 час.
	Производство пузырьков газа		Конкретные растворителя
	Изменение цвета		Осадки через 24 часа
	Немедленная мутность		Осадки через 15 часов
	Способы введения		Интравенная, внутривенная инфузия
	Внутримышечный		Библиография

	Раствор для перорального приёма		Стабильность фармацевтических препаратов
	Origine		Наполнитель
	Таблетки		Коммерческий лекарственный продукт
	Пластиковая бутылка		Порошок
	Шприц		Словарь